Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

NZ sharemarket shakes off Wall Street fall to end firm
Markets

NZ sharemarket shakes off Wall Street fall to end firm

New Zealand shares shook off weakness in overseas markets.

Jamie Gray 07 Nov 2025
Seeka uncovers $350k fraud, sacks employee
Markets

Seeka uncovers $350k fraud, sacks employee

Three companies have been identified as being involved in the fraud, CEO says.

John Anthony 07 Nov 2025
Smyth to stay on as Spark chair for another year
Markets

Smyth to stay on as Spark chair for another year

The past year had been one of the toughest in Spark's history, chair says.

John Anthony 07 Nov 2025